Year archive

Akeso, Inc. — 2025 filings

All 41 regulatory filings released by Akeso, Inc. (9926) in 2025, sourced directly from the official regulator.

41 Filings

2025 Period

2025 filings (41)

Filing	Released	Lang
CONTINUING CONNECTED TRANSACTIONS PURSUANT TO RULE 14A.60 OF THE LISTING RULES Regulatory Filings	2025-12-31	English
VOLUNTARY ANNOUNCEMENT - ALL APPROVED INDICATIONS OF AKESO'S 5 MARKETED DRUGS INCLUDED IN THE MOST RECENT NRDL Regulatory Filings	2025-12-07	English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 November 2025 Regulatory Filings	2025-12-04	English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 October 2025 Regulatory Filings	2025-11-05	English
VOLUNTARY ANNOUNCEMENT - HARMONI-6 RESULTS PUBLISHED IN THE LANCET & 2025 ESMO mPFS 11.14m vs 6.9m (HR=0.60, P50.0001) FOR IVONESCIMAB PLUS CHEMO VS TISLELIZUMAB PLUS CHEMO IN 1L ADVANCED SQ-NSCL Regulatory Filings	2025-10-20	English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 September 2025 Share Issue/Capital Change	2025-10-08	English
2025 INTERIM REPORT Interim / Quarterly Report H1 2025	2025-09-30	English
Next Day Disclosure Return Share Issue/Capital Change	2025-09-04	English
COMPLETION OF PLACING OF NEW SHARES UNDER GENERAL MANDATE AND PLACING OF EXISTING SHARES Share Issue/Capital Change	2025-09-04	English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 August 2025 Regulatory Filings	2025-09-03	English
PLACING OF NEW SHARES UNDER GENERAL MANDATE AND PLACING OF EXISTING SHARES Share Issue/Capital Change	2025-08-28	English
TERMS OF REFERENCE OF THE NOMINATION COMMITTEE Governance Information	2025-08-26	English
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2025 Interim / Quarterly Report H2 2025	2025-08-26	English
DATE OF BOARD MEETING Regulatory Filings	2025-08-14	English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 July 2025 Regulatory Filings	2025-08-06	English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 June 2025 Regulatory Filings	2025-07-04	English
POLL RESULTS OF THE ANNUAL GENERAL MEETING AND THE EXTRAORDINARY GENERAL MEETING HELD ON MONDAY, JUNE 30, 2025 Declaration of Voting Results & Voting Rights Announcements	2025-06-30	English
FORM OF PROXY FOR THE EXTRAORDINARY GENERAL MEETING TO BE HELD ON MONDAY, JUNE 30, 2025 Proxy Solicitation & Information Statement	2025-06-11	English
NOTICE OF EXTRAORDINARY GENERAL MEETING Proxy Solicitation & Information Statement	2025-06-11	English
PROPOSED GRANT OF SHARE OPTIONS AND RSUS TO DR. XIA AND NOTICE OF EXTRAORDINARY GENERAL MEETING Proxy Solicitation & Information Statement	2025-06-11	English
FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON MONDAY, JUNE 30, 2025 Proxy Solicitation & Information Statement	2025-06-08	English
NOTICE OF ANNUAL GENERAL MEETING Proxy Solicitation & Information Statement	2025-06-08	English
PROPOSED GRANTING OF GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES; PROPOSED RE-ELECTION OF RETIRING DIRECTORS; PROPOSED RE-APPOINTMENT OF AUDITORS; AND NOTICE OF ANNUAL GENERA Proxy Solicitation & Information Statement	2025-06-08	English
VOLUNTARY ANNOUNCEMENT - NMPA APPROVED THE SNDA FOR CADONILIMAB (PD-1/CTLA-4) AS FIRST-LINE TREATMENT FOR CERVICAL CANCER Regulatory Filings	2025-06-05	English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 May 2025 Regulatory Filings	2025-06-04	English
GRANT OF SHARE OPTIONS AND RESTRICTED SHARE UNITS Director's Dealing	2025-05-26	English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 30 April 2025 Share Issue/Capital Change	2025-05-08	English
Notification Letter and Reply Form to Non-registered Holders - Reminder letter regarding the Arrangement of Electronic Dissemination of Corporate Communications Regulatory Filings	2025-04-29	English
Notification Letter and Reply Form to Registered Shareholders - Reminder letter regarding the Arrangement of Electronic Dissemination of Corporate Communications Regulatory Filings	2025-04-29	English
2024 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT Environmental & Social Information	2025-04-29	English
2024 ANNUAL REPORT Regulatory Filings	2025-04-29	English
VOLUNTARY ANNOUNCEMENT - NMPA APPROVED THE 2ND INDICATION FOR IVONESCIMAB (PD-1/VEGF) AS 1L TREATMENT FOR NSCLC WITH POSITIVE PD-L1 EXPRESSION Regulatory Filings	2025-04-27	English
VOLUNTARY ANNOUNCEMENT - FDA APPROVED ANNIKO (PENPULIMAB-KCQX, PD-1) IN TWO INDICATIONS FOR COMPREHENSIVE TREATMENT OF ADVANCED NASOPHARYNGEAL CARCINOMA Regulatory Filings	2025-04-25	English
VOLUNTARY ANNOUNCEMENT - AK112-306/HARMONI-6 MET PRIMARY ENDPOINT OF PFS SUPERIORITY IVONESCIMAB PLUS CHEMO DEMONSTRATED A STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL BENEFITS VS. TISLELI Regulatory Filings	2025-04-23	English
VOLUNTARY ANNOUNCEMENT - NMPA APPROVED NDA OF (EBDAROKIMAB, IL-12/IL-23) Regulatory Filings	2025-04-21	English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 March 2025 Regulatory Filings	2025-04-03	English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2024 Earnings Release FY 2024	2025-03-30	English
DATE OF BOARD MEETING Report Publication Announcement	2025-03-19	English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 28 February 2025 Share Issue/Capital Change	2025-03-05	English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 January 2025 Regulatory Filings	2025-02-06	English
Monthly Return of Equity Issuer on Movements in Securities for the Month ended 31 December 2024 Share Issue/Capital Change	2025-01-07	English